GOTHENBORG, Sweden, July 14 PharmaSurgics AB.successfully completes Phase I clinical study showing their novel candidatedrug PXL01 is safe and well tolerated. Initially developed to preventpost-surgical adhesion formation following hand surgery the product combinesthe pharmacological effect of PXL01 with the physical barrier effect of thevehicle, and has the potential to be the first anti-adhesion drug on themarket. 'These results provide the foundation for proceeding to the nextphase, proof of concept study in patients,' said Fredrik Sjovall, CEO ofPharmaSurgics, adding 'the proof of concept study in patients of flexortendon repair surgery is scheduled to start in December 2009.'
Post-surgical adhesions are bands of scar tissue connecting anatomicsites in the body that should not normally be connected. These develop afteralmost every type of surgery and cause symptoms such as restricted jointmobility, chronic pain, intestinal obstruction and re-operativecomplications. Following flexor tendon repair surgery post-surgical adhesionslead to decreased strength and function of the affected joints, extensivepost-operative physiotherapy and extended periods of sick leave.
PharmaSurgics in Sweden AB is a Gothenburg based biotech company thatdevelops and commercializes a novel treatment for preventing harmful scarringand promoting wound healing after surgery. PharmaSurgics product concept isbased on proprietary synthetic peptides which have strong anti-inflammatoryand anti-infectious properties. The company was founded in 2005, based onextensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarkerat Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is aKarolinska Development portfolio company.For further information please contact Fredrik Sjovall, CEO of PharmaSurgics Ph: +46-31-762-29-01 Email: [email protected]
SOURCE PharmaSurgics AB